EUVIMEDEUVIMED entdecken
Open Access

Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis

Filip Stanicic iD, Dimitrije Grbic iD, Djurdja Vukicevic iD, Vladimir Zah iD

Journal of Comparative Effectiveness Research · 2024

DOI: 10.57264/cer-2023-0183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Filip Stanicic und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Economics & Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON L5A 2X7, Canada. Hauptthemen laut MEDLINE: Buprenorphine, Analgesics, Opioid, Low Back Pain, Chronic Pain. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Explore the safety of Belbuca® (buprenorphine buccal film), buprenorphine transdermal patches and oral opioids for chronic low back pain (cLBP) treatment.

Methods

The retrospective analysis of the MarketScan Commercial database (2018–2021) included treatment-naive cLBP adults. The first date of buprenorphine (Belbuca and transdermal patch) or opioid prescription was index date. Cohorts were defined based on the index medication. Observation included a 6-month pre-index period, while post-index lasted until the end of continuous insurance coverage. There were 44 relevant treatment-emergent adverse events (TEAEs) identified in the literature. Incidence rate ratio (IRR) and incidence rate difference (IRD) were used to compare serious TEAE rates (in 1000 person-years) between cohorts. Propensity-score matching minimized the selection bias.

Results

Buprenorphine had lower rates of 15 serious TEAEs than oral opioids (all p ≤ 0.037), while higher rates only for serious dizziness (IRR 2.44, p = 0.011; driven by Belbuca), opioid abuse/dependence (IRR 3.13, p = 0.004; driven by patches) and cholecystitis (IRD 20.25, p = 0.044; an outlier). Additionally, a comparison between Belbuca and oral opioids showed lower rates of 13 serious TEAEs (all p ≤ 0.024) and a higher serious dizziness rate (IRR 3.17, p = 0.024). Although the rates of serious opioid abuse/dependence were similar (24.60 vs 26.93, p = 0.921), all Belbuca patients and none of the opioid patients had a positive history of these events. Belbuca also had lower rates of five serious TEAEs than transdermal patches (all p ≤ 0.018), including a serious opioid abuse/dependence (IRR 0.04, p < 0.001), but higher rates of serious cholecystitis (IRD 52.17, p = 0.035; an outlier) and suicidal ideation (IRD 156.50, p < 0.001; an outlier).

Conclusion

Buprenorphine had a better safety profile than oral opioids in cLBP treatment. Belbuca showed a more favorable TEAE profile than buprenorphine transdermal patches and oral opioids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineAnalgesics, OpioidLow Back PainChronic PainHumansRetrospective StudiesFemaleMaleAdultMiddle AgedAdministration, OralInsurance Claim ReviewTransdermal PatchYoung AdultOpioid-Related Disorders

Stichwörter der Autor:innen

buprenorphine buccal filmbuprenorphine patchchronic painlong-acting opioidsreal-world evidencesafetyschedule II opioidsschedule III opioidserious adverse eventsshort-acting opioids

Substanzen

BuprenorphineAnalgesics, Opioid

Autor:innen und Institutionen

  • Health Economics & Outcomes Research Department, ZRx Outcomes Research Inc., Mississauga, ON L5A 2X7, Canada.

ORCID-Profile: Filip Stanicic, Dimitrije Grbic, Djurdja Vukicevic, Vladimir Zah

Zitieren

APA

Stanicic, F., Grbic, D., Vukicevic, D., & Zah, V. (2024). Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0183

Vancouver

Stanicic F, Grbic D, Vukicevic D, Zah V. Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2023-0183

BibTeX
@article{Stanicic2024,
  author = {Stanicic, Filip and Grbic, Dimitrije and Vukicevic, Djurdja and Zah, Vladimir},
  title = {Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  doi = {10.57264/cer-2023-0183}
}
Kostenlos starten →